Darren Sissons

Policy error is a market threat. Central banks so far do nothing in the face of inflation; the longer the delay in raising rates, the greater the risk. During tax-loss selling, look at longer terms of owning your stocks, not quarterly. Anything that benefit from rising rates, those stocks benefit your portfolio. ENB, for example, raised their dividend today. There's a lot of trading these days, but that makes your broker rich. Asia is very cheap now. Europe is also cheap. He likes ESG themes. The banks are inexpensive. Logistics companies have seen a bonanza, so could face downside.

You make money when buy, not sell, a stock, when you buy something at a discount. Example: buying in real estate a decade ago and sell now. It's critical when companies are on sale and face growth.

You need some exposure to the second-biggest economy, China. Do it directly or indirectly, like a copper company? Or a combo? China's trading regulations have hurt BABA. Beijing wants investments to move from tech to auto and rails. BABA, though, will remain a great, solid company. Volatility offers entry levels. BABA trades at a discount to American tech peers. Long-term, it's a great company that won't disappear any time. He also likes Tencent, pharmas and cars in China.

Generally, he doesn't like share dilution, but ask the reason why. For instance, to buy assets and grow the company is a positive. AQN is fine; it will benefit from the ESG movement. Likes it. Renewables and AQN have had a tough year, but it offers good value now and long-term growth.

When does it make sense for a foreign buyer to buy an ADR/OTC... When you buy an ADR, it'll be cheaper paying constant ADR fees. He tends to buy stocks in local markets and seldom trades stocks. Over time, the relatively inexpensive buying foreign. If you trade a lot, then buy local markets.

In Canada, tech stocks is the tuck-in acquisition model. However, tech PEs in Canada are steep now. ENGH's CEO may be waiting for a buying opportunity of a cheap company, but offering value; he has a good track record. Companies that do more of these deals drive revenues. ENGH offers reasonable long-term growth, particularly since it has underperformed in the past year.

The long-term chart shows a phenomenal run. A while ago, it was dead money for 10 years, then moved into cloud computing, which gave it a huge step up. Question: Will the cloud space see more competition? Tech has seen a big profit, so he'd take profits to de-risk. At least sell your cost base.

2020 growth was fantastic, but now there are so many other choices in videoconferencing. ZM has retraced a lot, and will likely decline further over time, until another company buys it, since Zoom is a single-product company. You can short it, but he isn't buying it.

(A Top Pick Nov 06/20, Up 5%) He's owned this for years, a great performer. It's penalized by the recovery trade. But everyone is still buying online and moving away from cash payments. He'd buy now.

(A Top Pick Nov 06/20, Up 20%) Has over 26 straight years of dividend growth, but can't catch a break from the market. He still likes it for its dividend, exposure to renewables (regulated assets) and its management. It's a bond proxy and a steady operator.

(A Top Pick Nov 06/20, Down 1%) They just announced huge inflows after they redeemed their stake in Roche. They continue to do (and will do) more tuck-in acquisitions. And yet, it's a stock that can't get any love. There's no big news in the pipeline. Strong balance sheet. Tuck-ins will continue and it's possible they will spin-off their generics business, so there are catalysts to grow. Cheap now, so it's a buying opportunity.

Telcos outside Canada are struggling and yet offer good value. The market is reaching for growth and will eventually benefit companies that pay larger dividends. VOD has been dead money for a while. However, it's good value now if you're long-term. It's a fixed-income proxy. But you may not see upside until rates rise.

They failed to control the mobile phone market as they once did in desktops, so this became dead money for a long while. It's trying to rebound by getting into the auto business. If so, shares will pop. A great company, INTC pays a good, safe dividend, and won't tumble as much in a tech sell-off. But they're not positioned in the right market now. It wouldn't hurt to own this, but it's not his first choice.

Eventually, a full, broad-spectrum vaccine will be in place to cover Covid. Will MRNA technology also develop drugs to tackle TV and HIV and other diseases. Novartis offers more a strong balance sheet and a just-announced $20 billion inflow, based on tuck-in acquisition. NVAX is fine, but there are better companies.

Patents expire in a year It's been a great story since the spin-out, but now it's challenged. Look at other opportunities, like Roche and Astrazeneca, for better opportunities.